Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD
Shenzhen Stock ExchangeTotal Valuation
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD carries a market capitalization of 2.22B, placing it among publicly traded companies globally. Its enterprise value stands at 2.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.22B |
| Enterprise Value | 2.83B |
Share Statistics
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD currently has 303.35M shares outstanding.
| Shares Outstanding | 303.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD trades at a trailing price-to-earnings ratio of 57.32. The price-to-sales ratio is 3.35, and the price-to-book ratio stands at 4.74.
| PE Ratio | 57.32 |
| PS Ratio | 3.35 |
| PB Ratio | 4.74 |
| P/TBV Ratio | 3.88 |
| P/FCF Ratio | 77.36 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD trades at an EV/EBITDA multiple of 28.58 and an EV/FCF ratio of 74.15. The EV/Sales ratio of 3.36 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 28.58 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.36 |
| EV / EBITDA | 28.58 |
| EV / EBIT | 28.58 |
| EV / FCF | 74.15 |
Financial Position
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD maintains a current ratio of 1.54, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.10, indicating elevated leverage, while an interest coverage ratio of 49.99 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.54 |
| Quick Ratio | 0.53 |
| Debt / Equity | 19.10 |
| Debt / EBITDA | 1.57 |
| Interest Coverage | 49.99 |
Financial Efficiency
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD posts a return on equity of 8.50 and a return on invested capital of 8.43.
| Return on Equity (ROE) | 8.50 |
| Return on Assets (ROA) | 3.46 |
| Return on Invested Capital (ROIC) | 8.43 |
| Return on Capital Employed (ROCE) | 3.49 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.30 |
Taxes
Over the trailing twelve months, Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD has paid 17.09M in income taxes, reflecting an effective tax rate of 19.09.
| Income Tax | 17.09M |
| Effective Tax Rate | 19.09 |
Stock Price Statistics
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD's stock has declined approximately -26.10887% over the past 52 weeks. The 50-day moving average sits at 8.24, while the 200-day moving average is 9.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.10887% |
| 50-Day Moving Average | 8.24 |
| 200-Day Moving Average | 9.48 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD generated 843.87M in revenue and converted that into 49.37M in net income, yielding earnings per share of 0.24. EBITDA reached 99.09M, while operating income came in at 99.09M.
| Revenue | 843.87M |
| Gross Profit | 565.20M |
| Operating Income | 99.09M |
| Pretax Income | 89.56M |
| Net Income | 49.37M |
| EBITDA | 99.09M |
| EBIT | 99.09M |
| Earnings Per Share (EPS) | 0.24 |
Balance Sheet
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD holds 234.61M in cash and equivalents against 155.45M in total debt, resulting in a net debt position of -131.26M. Total book value stands at 597.40M, with working capital of 239.21M providing operational flexibility.
| Cash & Cash Equivalents | 234.61M |
| Total Debt | 155.45M |
| Net Debt | -131.26M |
| Equity (Book Value) | 597.40M |
| Book Value Per Share | 1.97 |
| Working Capital | 239.21M |
Cash Flow
After subtracting -36.59M in capital expenditures, free cash flow totaled -36.59M - equivalent to -0.12 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -36.59M |
| Free Cash Flow | -36.59M |
| FCF Per Share | -0.12 |
Margins
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD operates with a gross margin of 66.98, reflecting its pricing power and cost economics. The operating margin of 11.74 and net profit margin of 5.85 provide insight into operational efficiency.
| Gross Margin | 66.98 |
| Operating Margin | 11.74 |
| Pretax Margin | 10.61 |
| Profit Margin | 5.85 |
| EBITDA Margin | 11.74 |
Dividends & Yields
The company's payout ratio of -2.80 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | -0.01 |
| Dividend Yield | N/A |
| Payout Ratio | -2.80 |
| Shareholder Yield | 0.55 |
| FCF Yield | 1.29 |
Stock Splits
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD's most recent stock split took place on May 10, 2017 with a 2:7 split ratio.
| Last Split Date | 5/10/2017 |
| Split Ratio | 2:7 |
Scores
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD posts an Altman Z-Score of 4.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.20 |